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TumorigenesisThe role of p53 as the ‘‘guardian of the genome’’ in differentiated somatic cells, triggering various
biological processes, is well established. Recent studies in the stem cell ﬁeld have highlighted a pro-
found role of p53 in stem cell biology as well. These studies, combined with basic data obtained
20 years ago, provide insight into how p53 governs the quantity and quality of various stem cells,
ensuring a sufﬁcient repertoire of normal stem cells to enable proper development, tissue regener-
ation and a cancer free life. In this review we address the role of p53 in genomically stable embry-
onic stem cells, a unique predisposed cancer stem cell model and adult stem cells, its role in the
generation of induced pluripotent stem cells, as well as its role as the barrier to cancer stem cell
formation.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The balance between genome stability and plasticity is crucial
in determining cell fate, yet this balance varies between somatic
and stem cells (SCs). In a somatic cell, p53 has a major role in trans-
lating stress signals into classic processes such as apoptosis, cell
cycle arrest, DNA repair and senescence, contributing to its main
role as the ‘‘guardian of the genome’’ [1]. However, p53’s function
in SCs varies in a context-dependent manner. Imbalance between
genome stability and plasticity may lead to intensive senescence
or apoptosis, which can result in a severe depletion of the func-
tional SC reservoir and to improper development or early aging.
This dilemma emphasizes the important balance between the
quantity and quality of SCs [2]. In recent years, p53 was found to
have great impact in processes such as cellular differentiation
[3–7], self-renewal [8,9] and plasticity [10,11], ensuring a balance
between genome stability and plasticity in normal SCs.
SCs have a profound impact on embryonic development and are
central for organ renewal during adult life [12]. As such, SC gen-
omes must be guarded to minimize genetic lesions that may occur
during their expansion and may lead to premature aging, failure to
repair tissue injury and to cancer [13–15]. Genomic stability and
ﬁdelity are a hallmark of pluripotent Embryonic Stem Cells (ESCs).
ESCs can differentiate into three lineages in the embryo, includinggerm cells [16]; thus genome stability is crucial for avoiding
tumorigenesis as well as preventing mutations from being passed
onto progeny. Indeed, ESCs have a low rate of spontaneous muta-
tions compared to somatic cells [17]. Adult Stem Cells (ASCs),
which reside in many tissues of the body, also hold the potential
for self-renewal and differentiation into speciﬁc cell lineages –
although they do not have the capacity to form an embryo. ASCs
proliferate through asymmetric cell division, giving rise to one
daughter SC and one transit-amplifying cell. Their activation occurs
during particular developmental stages or after external injury,
and their regulation is strictly controlled in their niches [18].
Dedifferentiation of somatic cells holds promise as a source for
patient-speciﬁc transplantation therapies. Conversion of differenti-
ated cells into a pluripotent state has been achieved by three meth-
ods: nuclear transfer – ﬁrst achieved by transferring the nuclei of
differentiated intestinal epithelium cells of feeding tadpoles into
enucleated recipient eggs [19,20]. The second method used fusion
of human amniocytes with differentiated mouse muscle cells,
which provided valuable insights but not as a source of cells for
regenerative medicine [21,22]. However, the major breakthrough
in the ﬁeld was provided by Takahashi and Yamanaka, who dem-
onstrated the induction of pluripotent SCs from mouse embryonic
ﬁbroblasts (MEFs) by introducing four deﬁned factors, Oct3/4,
Sox2, Klf4 and c-Myc (OSKM) under Embryonic Stem (ES) cell cul-
ture conditions [23]. This development of induced pluripotent
embryonic stem cells (iPSCs) provides insights into the biology of
ESCs. Since then iPSCs have been generated from multiple tissues
by various combinations of factors or techniques [24]. These iPSCs
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Fig. 1. p53 the barrier to cancer stem cells formation. p53 maintains a pool of
normal SCs by controlling the quantity and quality of SCs. p53 restricts processes of
in vivo dedifferentiation and in vitro reprogramming, preventing the transforma-
tion and dedifferentiation of differentiated cells into CSCs. SCs have the potential to
undergo mutation in p53. In heterozygous p53 SCs LOH can occur as a DNA repair
process, leading to the loss of the mutant allele and ensuring the quality of the SCs.
In the case where the WT allele is lost CSCs will be formed.
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tiate into all three germ layers in vitro, form teratomas (a differen-
tiated and non-malignant tumor) when injected into
immunodeﬁcient mice, and produce chimeric live pups when in-
jected into blastocyst or germ cells. In fact, germ-line transmission
is the most convincing demonstration of true pluripotency. Re-
cently, it was shown that removing epigenetic barriers can im-
prove reprogramming efﬁciency and induce pluripotency in
nearly all the cells in a deterministic manner [25]. Yet the major
concern in the use of iPSCs for therapeutic means – their tumori-
genic potential – still remains. Thus, elucidation of the speciﬁc
master regulators of pluripotency may enable efﬁcient induction
of safer cells to be used in regenerative medicine in numerous dis-
eases. Indeed, studies by Buganim et al. have shed some light on
the phases of transcriptional and epigenetic changes that occur
during reprogramming and on the hierarchy of the regulators in-
volved [26,27]. These studies may provide criteria that will allow
assessment of iPSCs quality.
Much attention in the SCs ﬁeld is drawn to the Cancer Stem Cell
(CSC) theory. The CSC theory is based on the developmental hierar-
chy seen in normal tissue, wherein the undifferentiated SCs reside
at the top, followed by a gradient of various degrees of differenti-
ated cells. Similarly, tumors are organized in a hierarchical order
that sustains a distinct subpopulation of CSCs. CSCs can divide
asymmetrically, giving rise to a bulk tumor cell and a CSC, keeping
the CSC reservoir small in numbers. Only the CSCs have the capa-
bility to initiate new tumors. These CSCs were found in a number
of human hematological and solid tumors and have been deﬁned
experimentally by their ability to seed new tumors [28]. Just as
normally proliferating tissues such as wounds are nourished and
regenerated by SCs, so is a tumor – which may be considered as
a ‘‘wound that never heals’’ [29] – nourished by tumor cells with
an unlimited renewal potential. Indeed, CSCs and SCs share func-
tions, such as self-renewal asymmetric cell division, the ability to
generate a large number of differentiated cells, and the expression
of speciﬁc markers [12,30,31]. Moreover, just as normal SCs have
the ability to migrate to distinct parts of the body where they exert
their functions, CSCs also seem to have the potential to migrate and
establish metastasis [32]. Taken together, it is not surprising that
SCs and CSCs share similar regulatory factors that modulate these
biological functions [33]. However, SC function remains under
physiological control, whereas the division and differentiation of
CSCs are decidedly not [34,35]. These uncontrolled pathways in-
clude those regulated by WNT/b-catenin, PTEN, TGF-b, Hedgehog,
Notch and Bmi-1 [36]. Moreover, CSCs are also resistant to chemo-
therapy and radiation and may be, as normal SCs are, protected
against various insults, likely by mechanisms such as quiescence,
expression of ATP binding cassette (ABC) pumps which may lead
to multidrug resistance, high expression of anti-apoptotic proteins
and resistance to DNA damage [37–39]. Unfortunately, CSC-rich
tumors are associated with aggressive disease and poor prognosis
[40] emphasizing the importance of unraveling their biology and
the need to develop means to combat them.
CSC may arise from the transformation of a normal ASC or pro-
genitor cell. Although the number of SCs is very small, they can un-
dergo continuous division for a long time and are thus more likely
to accumulate the molecular mutations that cause tumorigenesis.
Indeed, Dick and colleges showed that only the transfer of a small
population of human leukemia cells, displaying the cell surface
markers of HSC, into immunodeﬁcient mice, rather than more dif-
ferentiated cells gave rise to new tumors. This suggests that normal
primitive SCs, rather than committed progenitor cells, are the tar-
get of leukemic transformation [41,42].
Other studies favor the option that CSCs may have taken advan-
tage of cellular plasticity and originate from differentiated cells
through a process of dedifferentiation [43]. Regulated dedifferenti-ation may be regarded as a cellular homoeostasis mechanism
through which tissues can regenerate after SCs are lost. For exam-
ple, single secretory cells from the epithelium of the mouse trachea
were able to dedifferentiate into multipotent SCs. This dedifferen-
tiation process was triggered upon SC ablation and was prevented
by direct contact of SCs with the committed cells, ensuring epithe-
lial architecture. The authors suggest that the reciprocal interac-
tion of stem and committed cells may have been designed to
ensure robust self-organizing properties in diverse tissue types
[44]. Recently, a role for p53 during salamander limb regeneration
was published. It was shown that the activity of p53 initially de-
creases and then returns to baseline. The down-regulation is re-
quired for formation of the blastema and is critical for cell cycle
reentry of post-mitotic differentiated cells, and the up-regulation
is necessary for the redifferentiation phase to muscle. The authors
suggest that the regulation of p53 activity is a pivotal mechanism
that controls the plasticity of the differentiated state during regen-
eration [45]. These studies indicate that dedifferentiation is a reg-
ulated process in homeostasis and regeneration. Unfortunately,
uncontrolled dedifferentiation may have cancerous consequences.
Although much knowledge on CSCs has been obtained in the past
years, how and when a CSC is formed in a particular tumor are still
open questions. The two ways to obtain CSC do not exclude each
other, but rather depend on the cancer type and context (Tables
1 and 2). Regardless of whether it is transformation of a progeni-
Table 1
Cancer types in which p53 aberrant ASCs has been shown to be involved in their
initiation and progression.
Cancer Stem cell Refs.
Multiple myeloma Hematopoietic stem/progenitor cells [136]
Leiomyosarcoma Fat-derived MSCs [92]
Fibrosarcoma (mouse model) Aged MSC [87]
Osteosarcoma MSC of the limb bud [137]
Glioma -glioblastoma NSCs [138]
Glioma- astrocytoma NSCs [94]
Ovarian cancer Ovarian stem-like cells [139]
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routes of transformation.
During the last several years the stem cell ﬁeld has expanded,
providing more questions than answers. The ﬁndings that induced
pluripotency and induced tumorigenesis are related processes, as
judged by gene expression proﬁles [46], and that CSC hierarchy
mimics normal SC hierarchy, emphasize the need for regulatory
proteins that will guard and maintain a cancer-free repertoire of
normal SCs. In this review we address the role of p53 in normal
SCs as well as CSC prevention. The fate of an intermediate phase
of SCs, namely those that harbor both wild type and mutant p53,
presenting a state predisposed to CSCs, will also be discussed.
2. p53 in the life of a normal stem cell
2.1. The role of p53 in ESCs
Over 30 years ago, a set of studies described the expression of
p53 in primary cell cultures obtained from embryos. High expres-
sion of p53 was observed in cell cultures of 12–14 day old mouse
embryos, which declined in cells of 16 day old embryos [47–49].
These studies, among others, highlighted that although p53 is
highly abundant in mouse ESCs [50,51], it was localized mainly
in the cytoplasm [52,53] and was found to be inactive [54,55]. In
contrast to mouse ESCs, in human ESCs p53 is localized in the nu-
cleus, in a deacetylated inactive state and at low levels [56]. In-
deed, whereas in somatic cells p53 classical response to DNA
damage is G1/S cell cycle arrest, apoptosis or cellular senescence,
this is not the case in mouse ESCs [55]. Although these observa-
tions are in line with the requirement of ESCs for rapid cell division
and self-renewal, they also present a paradox; how do ESCs man-
age to maintain a stable genome without the classical functions
of the ‘‘guardian of the genome’’? Does p53 exert its guardian func-
tions through other biological pathways? Moreover, the observa-
tions from the early nineties that p53 knockout mouse embryos
developed normally, suggesting that p53 is redundant in embryo-
genesis [57], prompted more questions on the role of p53 inTable 2
Cancers and tumor lines in which p53 aberrations resulted in dedifferentiated phenotype
Cancer Phenotype
Chondrosarcoma High grade/dedifferentiated zones of chond
Liposarcoma Dedifferentiated liposarcoma
Adenoid Cystic Carcinoma (AdCC) Dedifferentiated AdCC
Thyroid carcinoma Poorly differentiated and undifferentiated t
Carcinoma Carcinomas from the p53 null and hemizyg
type mice
Glioma Dedifferentiation of astrocyte during tumor
Wilms tumor Strong association between the appearance
Undifferentiated-Gastric Carcinoma
(UGC)
The inactivation of wild-type TP53 is an ear
Medulloblastoma TP53-ARF pathway is disrupt in anaplastic
Hepatocellular carcinoma Mutant p53 may have contributed to dediffembryogenesis. Since then many studies have shed light on the
important roles played by p53 in embryonic development. Indeed,
a role in regulating suppression of self-renewal and induction of
differentiation after DNA damage was assigned to p53. p53 binds
and suppress the promoter of the master transcription factor Na-
nog and the pluripotency factor Oct4, which are highly abundant
in mouse ESCs and drive self-renewal and the maintenance of an
undifferentiated state [58,59]. Thus, suppression of these two
genes in DNA damaged mouse ESCs will force differentiation [6]
into cell types that can be subjected to classical p53 processes such
as cell-cycle arrest or apoptosis. Recently, it was reported that
silencing of Oct4 in human ESCs leads to the activation of p53,
through the reduction in the expression of Sirt1, a deacetylase
known to inhibit p53 activity, leading to increased acetylation of
p53 at lysine 120 and 164 and promotion of differentiation [60].
Moreover, p53 was found to activate the expression of miR-34a
and miR-145, which in turn repress stem cell factors Oct4, KLF4,
LIN28A and Sox2 and prevent backsliding to pluripotency [56].
Furthermore, it was reported that a single aurora kinase A (Aur-
ka)-mediated phosphorylation event is largely responsible for
inactivating p53 and that in the absence of Aurka, increased p53
signaling promotes mouse ESC differentiation [61]. Recently an
in-depth study of the genes regulated by p53 in human ESCs in re-
sponse to early differentiation, induced by retinoic acid, revealed
that p53 promotes differentiation of human ESCs by activating
expression of developmental transcription factor genes involved
in patterning, morphogenesis and organ development. Differentia-
tion-speciﬁc p53 gene targets in human ESCs include several mem-
bers of the homeodomain family (HOX, LHX, DLX, PAX), the
forkhead family of FOX genes, the SOX gene family, and members
of the TBX family of genes, all of which regulate a wide variety of
developmental processes [62]. In addition, p53 targets members
of the CBX family, speciﬁcally CBX2 and CBX4, which are part of
the Polycomb complex and are crucial for cell-fate determination
[63]. Moreover it was found that several p53 gene targets are down
regulated during RA-mediated differentiation, including genes that
direct mesodermal differentiation (FOXO3, KLF6, HDAC5, HDAC6)
and telomere repeat binding factor TERF1, associated with pluripo-
tency [64]. In all, in ESCs p53 seems to be a homeostatic protein
ensuring proper development by governing pluripotency potential.
In ESCs with damaged DNA p53 will force differentiation by har-
nessing many developmental pathways.
2.2. The role of p53 in iPSCs
Many studies have addressed the role of p53 in the biology of
iPSCs. p53 was found to have a major role in the generation of iPS-
Cs both in attenuating reprogramming as well as in quality control
of the reprogramming. Indeed, in agreement with others, we found
that WT p53 constrains iPSC generation in vitro [65–73]. It was.
Refs.
rosarcoma [140,95]
[141]
[142,143]
hyroid tumors [144,145,97]
otes are more frequently undifferentiated than those from wild- [96]
igenesis [138]
of anaplastic clones and TP53 mutations [146]
lier event before dedifferentiation to mixed-type UGC [147]
medulloblastoma [148,149]
erentiation during the development of HCC [150,151]
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quency of iPSC generation. Furthermore, it was suggested that p53
may induce cell cycle arrest and apoptosis and thus function as a
barrier to select exclusively perfect reprogrammed SCs [74]. A
p53 mediated DNA damage response was shown to limit repro-
graming to ensure iPSC genomic integrity [70]. An additional role
of p53 during reprogramming may be an indirect effect on cell pro-
liferation [75]. One scenario suggests that p53 up regulates miR-
199a-3p, which imposes G1 cell cycle arrest [76]. Another study
demonstrated that p53 exerts its suppression of iPSC generation
through the axis of p53-upregulated modulator of apoptosis
(PUMA) [77]. We showed that p53 restricts mesenchymal-to-epi-
thelial transition (MET) during the early phases of reprogramming
and that this effect is primarily mediated by the ability of p53 to
inhibit Klf4-dependent activation of epithelial genes [11]. Recently
we have reported that iPSCs generated from homozygous mutant
p53 MEFs, using only 2 transcription factors (Oct4 and Sox2),
exhibited fully reprogrammed iPSC phenotype in vitro yet formed
malignant terato-carcinomas in vivo, instead of the benign terato-
mas induced by the WT p53 iPSCs [73]. It is conceivable that these
are pre-iPSCs [78] that may represent cancer iPSCs. Latest studies
in the ﬁeld suggest that the reprogramming process is comprised
of an early stochastic phase and a late hierarchical one [26]. Reac-
tivation of p53 at any of the stages hampers the formation of iPSC
clones [79]. This suggests that p53 is not a transient roadblock, but
rather a full-time monitoring agent. Recently, homologous recom-
bination (HR) pathway genes were found to be necessary for the
reprogramming process. Interestingly, in the absence of p53, cells
with a defective HR pathway could undergo reprogramming,
allowing the generation of iPSCs with genetic aberrations, empha-
sizing the role of p53 in the quality control of this process [80]. In
all, this suggests that in addition to the rate-limiting role p53 plays
in reprogramming it also has a quality control role, ensuring the
generation of proper cancer-free iPSCs.
2.3. The role of p53 in ASCs
Under physiological conditions, an optimal balance exists be-
tween the maintenance of a sufﬁcient ASC pool for tissue regener-
ation and the elimination of severely damaged SCs, thus ensuring
maximal longevity. However, when encountering severe DNA dam-
age programmed cell death or, alternatively, temporary or perma-
nent cell cycle arrest is induced. The latter, which prevents cancer
development, may tilt this ﬁne balance and by the same token
cause depletion in the SC reservoirs leading to long-term negative
effects [81]. Although damage can be repaired in cells through
one or more of the many sophisticated genome maintenance path-
ways, DNA repair and incomplete restoration of chromatin after
substantiate damage may produce sequence mutations and epi-
mutations, both of which have been shown to accumulate with
age. The accumulation of faulty DNA containing mutations and/or
epi-mutations in aged tissues increases cancer risk [2]. As p53 is re-
garded as the ‘‘guardian of the genome’’ [1] it is not surprising that
dysfunction of p53 will affect processes critically dependent on
genomic ﬁdelity such as proliferation, differentiation and transfor-
mation of various ASCs.
The term ASCs includes many types of SCs, the more familiar of
which are mammary gland SCs, neural SCs, hematopoietic SCs and
mesenchymal SCs (MSCs). In this review we will address only the
role of p53 in MSCs. MSCs represent a population of adult hetero-
geneous multipotent stem cells, which can be isolated from many
adult tissues throughout the body and are able to self-renew and
differentiate into various cell types of mesodermal origin [82,83].
p53 was shown to control differentiation of MSCs [4,84]. We and
others have demonstrated that the absence of WT p53 [85] orthe presence of a mutant p53 (unpublished results) confers selec-
tive advantages in the acquisition of typical MSC markers along
with an increased proliferation of BM-derived MSC progenitors.
Both knockout p53 [85] and mutant p53 mice (unpublished result)
contained a larger number of colony forming precursors compared
to WT progenitors. Furthermore, knockout p53 MSCs presented
genomic instability with an increased expression of c-MYC [85].
MSC strains derived frommutant p53 also exhibited genome insta-
bility as judged by spectral karyotyping analysis (unpublished re-
sults). Interestingly, chromosome 11, where the p53 gene resides,
exhibited major alterations that increased with age. A role for
p53 in MSC aging may be suggested by the speciﬁc decrease in
p53 RNA and protein in MSCs during the aging process, which does
not occur in heart or spleen and may explain how MSCs avoid age-
related senescence [86]. Moreover, aged MSCs were shown to exhi-
bit spontaneous expression of embryonic factors and p53 point
mutations, suggesting that mesenchymal tumors may have origi-
nated from aged MSCs [87]. Interestingly, MSCs also have a tumor
promoting effect as supportive cells. p53 status in tumor stromal
cells has a key role in tumor development by modulating immune
responses. The tumor-promoting effect of p53-deﬁcient MSCs was
not observed in immune-compromised mice, indicating that the
immune response has a critical role [88]. Altogether, p53 plays
an essential role in MSC proliferation, maintaining their quantity
as well as assuring their quality by preventing their transforma-
tion. The decrease in p53 levels upon aging or the acquisition of
a mutation in the p53 gene may contribute to the high risk of
MSC sarcomagenesis and to the role of MSCs in supporting
carcinogenesis.
3. p53 as the barrier to formation of CSCs
CSCs could arise from accumulation of genetic insults in normal
stem or progenitor cells or by dedifferentiation of existing differen-
tiated cells. One example of the transformation of stem/progenitor
cells into CSCs is provided by MSCs, which were proposed as can-
didate cells of origin for several sarcoma types [89]. Increasing evi-
dence suggests that MSCs that acquire mutations in oncogenes or
tumor suppressors may function as tumor initiating cells (TICs)
leading to de novo tumor formation. In this regard MSCs might
be the TICs capable of initiating sarcomagensis [90] as was shown
for hematopoietic SCs, which may serve as TICs for hematopoietic
malignancies [41]. Several studies in mouse models have indicated
that p53 deﬁcient MSCs may lead to sarcomagenesis. Transforma-
tion of MSCs seems to be highly dependent on alterations in the
p21/p53 pathway, mainly by the abolishment of WT p53, but not
on the retinoblastoma pathway [90–93]. Moreover, analysis of
ﬁbrosarcomas derived from aged mice showed that these tumors
may have originated from MSCs harboring mutated p53. Further-
more, MSCs isolated from young mice and then aged in culture re-
vealed the acquisition of clinically signiﬁcant p53 mutations [87].
Another example of tumors originating from SCs was provided
by mouse models based on conditional inactivation of p53, NF1
and Pten. This study showed that brain tumors originate from neu-
ral stem/progenitor cells while more mature cells cannot form tu-
mors [94], identifying SCs as the cell of origin of CSCs. Table 1
provides examples of cancer types in which p53 aberration in ASCs
has been shown to promote initiation and progression.
Reports on the link between p53 loss and the differentiation
state of tumors were ﬁrst published about 20 years ago [95–98].
Those studies showed that the high grade/de-differentiated pheno-
type of some sarcomas and carcinomas correlates with p53 loss and
increasedmalignancy. Although these reports were consistent, they
received little attention. Only after the burst of the reprogramming
era came the understanding that all cell types have the potential to
2584 R. Aloni-Grinstein et al. / FEBS Letters 588 (2014) 2580–2589dedifferentiate. In addition, reprogramming only occurs in a very
small percentage of the transfected cells, suggesting the existence
of reprogramming barriers. Indeed, we and others showed that
down regulation of p53 enhances the efﬁciency of iPSC generation,
whereas re-expression of p53 in p53 null MEFs markedly impedes
this [65–73]. In addition, we have shown a new gain-of-function
property of mutant p53 that enhances reprograming efﬁciency be-
yond that of p53 null MEFs. However, homozygous mutant p53 iPS-
Cs formed malignant terato-carcinomas in vivo, perhaps
recapitulating the transition of a differentiated p53 mutant cell to
a dedifferentiated CSC. Others have extended our observation, dem-
onstrating that the Myc pathway cooperates with the p53-R175H
human mutant protein to disrupt the efﬁciency of reprogramming
and that different mutant alleles of p53 have diverse efﬁciencies
in enhancing iPSC colonies formation [79]. Thus, it is conceivable
that a differentiated cell in the body gains mutations that drive
the ﬁrst phase of the cancer phenotype. Following a second hit of
a p53 mutation, the barrier of dedifferentiation and formation of
CSCs is removed. Indeed, an analysis of human tumors revealed that
poorly differentiated aggressive tumor express an ESC transcription
signature as observed in SCs [99]. Interestingly, breast, lung and
prostate tumors with an ESC signature were found to contain a
p53 mutation. In contrast, well-differentiated tumors contained a
WT p53 [100,101]. Onemechanismbywhich p53 prevents dediffer-
entiation is by binding to the promoter of CD44, one of the better
known CSCmarkers, repressing its expression. Interestingly, consti-
tutive expression of CD44 blocks p53 dependent apoptosis leading
to cells resistant to doxorubicin [102]. Moreover, loss of p53 may
lead to increased expression of the multidrug-resistance genes
(ABCB1 orMDR1) and to chemotherapy resistance. Table 2 provides
examples of cancers and tumor lines in which p53 aberrations re-
sulted in a dedifferentiated phenotype.4. Facing a chronic DNA insult – the story of the p53
heterozygous stem cells
At the junction between normal SCs and CSCs lay the heterozy-
gous p53 SCs, namely SCs which concomitantly express a func-
tional WT p53 and a mutant p53. Such a genotype is presented
in Li-Fraumeni syndrome (LFS) patients. LFS is a rare type of cancer
predisposition syndrome associated with germ line p53 mutations
[103]. It appears that in LFS patients, as well as corresponding
mouse models [104], the WT p53 is dominant over the mutated
p53 allele, and they apparently develop normally. Only later in
adult life do they acquire a wide spectrum of tumors, including
bone and soft-tissue sarcomas, acute leukemia, early onset of
breast cancer, brain cancers such as glioblastoma, and adrenocorti-
cal tumors occurring over a wide age range [105]. Approximately
60% of the initially analyzed tumors exhibited loss of heterozygos-
ity (LOH) in the p53 locus. The remaining 40% bypass the suppres-
sive effect of the WT allele by diverse mechanisms such as
promoter hypermethylation [106], increased activity of Mdm2,
the E3 ligase responsible for p53 ubiquitination [107], by impairing
other components of the p53 pathway [108] or by the enhanced
oncogenic potential of missense p53 mutations that are common
in both LFS and sporadically mutation somatic cells [109]. Gain
of function mutants or those showing dominant negative features
may be sufﬁcient to induce tumor formation in the presence of the
WT gene, especially in context of other genetic or environmental
insults [105,110,111].
The mouse model of LFS (R172H which is homologous to hu-
man R175H hot-spot mutation) holds great promise to unravel
questions regarding the role of p53 in SCs of various origins and
functions. As SCs harboring exclusively either WT or mutant p53
represent an end-point of either a normal or a mutated SC, thep53 heterozygous SC may give a ‘‘snap shot’’ on the process of
tumorigenesis in SCs, as manifested by the LOH process. Impor-
tantly, this mouse model reﬂects the majority of p53 aberrations
in human malignancies, which are missense mutations (75%)
[112]. Moreover, it is tempting to speculate that the presence of
the mutant p53 in these heterozygous SCs endows them with
CSC characteristics. This speculation is based on the fact that
although p53+/ and p53+/R172H tumors show similarities, only oste-
osarcomas and carcinomas from p53+/R172H mice metastasize to
various organs [104].
We have established ESCs and MSCs derived from heterozygous
p53 LFS mice and generated iPSCs from MEFs of these mice. This
panel of cells enables us to evaluate the impact of p53 LOH on
tumorigenesis as a function of cell origin. Heterozygous p53 MEFs,
an example of somatic cells, undergo in vitro p53 LOH in a robust
manner. In contrast, the frequency of p53 LOH varied among the
various SCs as a function of their genome stability. It is well ac-
cepted that ESCs have a high genome stability and ﬁdelity mainly
due specialized mechanisms aimed at preserving their genome
[17]. Indeed, no p53 LOH was observed in heterozygous p53 ES
cells that exhibited stemness characteristics typical of WT p53
ESCs (unpublished results). With iPSCs heterozygous for p53 the
situation is less deﬁned. iPSCs, on the one hand, resemble ESCs
and are considered fairly genomically stable. On the other hand,
iPSCs are generated from MEFs, which were shown to be less sta-
ble. Although both WT and mutant p53 iPSCs present normal SC
markers, mutant p53 iPSCs appear earlier with greater reprogram-
ming efﬁciency. Moreover, when injected in vivo the mutant iPSCs
give rise to malignant tumors [73]. Heterozygous p53 iPSCs resem-
ble WT p53 iPSCs- both exhibit similar rates of iPSC formation.
However, about 20% of the heterozygous p53 iPSC clones did un-
dergo LOH, giving rise to iPSCs that resemble p53 mutant iPSCs,
which induce malignant tumors in mice. The observation that all
heterozygous p53 MEFs undergo p53 LOH but the majority of het-
erozygous p53 iPSCs do not, suggests that reprograming from a less
stable somatic cell into a more stable SC triggers mechanisms that
guard genome ﬁdelity. It seems that in ESCs and iPSCs the presence
of a functional WT p53 is sufﬁcient to maintain genome stability.
Thus, ESCs and iPSCs employ mechanisms, yet to be deﬁned, to
prevent p53 LOH. Moreover, an in-depth examination of single cell
sub-clones of iPSCs revealed that a small fraction of cells lose their
mutant allele rather than the WT p53 allele (unpublished results).
This phenomenon of bi-directional p53 LOH emphasizes the great
efforts made by iPSCs to maintain a stable genome. Since emerging
data suggests that dedifferentiation is a natural homeostasis pro-
cess [44], it is conceivable that p53, as a ﬁrst line of defense, regu-
lates and controls the processes of dedifferentiation in vivo and
reprogramming in vitro. In the event that this control checkpoint
is compromised, a second line of defense will be triggered. This line
of defense includes the attenuation of p53 LOH, which may other-
wise lead to the loss of the WT p53, or the activation of a DNA re-
pair LOH process leading to the loss of the mutant p53 allele. Taken
together, it appears that p53 functions to maintain a balance be-
tween somatic cells and SCs. Moreover, great efforts are made to
sustain a functional WT p53 in SCs and to ablate the mutant p53,
ensuring genome stability.
LFS patients and LFS mouse models predominantly develop sar-
coma ofmesenchymal origin [103,104]. Asmentioned above, sarco-
mas may arise from damaged MSCs. Although sarcomas are one of
the most dominant tumor types in LFS patients, as well as in the
mouse and rat LFS models [103,104,113], no data so far has pointed
to a p53 LOH process occurring in SCs of mesenchymal origin. The
availability of heterozygous p53 mice at various ages makes it pos-
sible to address the above question, both in vitro and in vivo, with
regard to aging. Interestingly, the in vitro p53 LOH process is more
pronounced in MSC isolates established from bone marrow of adult
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function of aging. Only the heterozygous p53 MSC isolates which
were established from adult mice induced sarcomas upon injection
into immunocompromised mice, suggesting that while p53 may be
a barrier to sarcomagenesis, its removal is not sufﬁcient to induce
cancer and further mutations are needed. Genotyping of single cell
clones revealed that, as in iPSCs, an attempt to lose the mutant al-
lele also occurs in MSCs but to a lesser extent. In contrast to hetero-
zygous p53 iPSCs, in heterozygous p53 MSCs most p53 LOH events
involved the loss of the WT allele, as expected from a less stable SC.
Similarly, ex-vivo examination of bone marrow progenitors has re-
vealed that p53 LOH is non-existent or very rare in bone marrow of
adolescent mice, reﬂecting the normal development and the lack of
tumors in patients and mice. However, the p53 LOH process was
accelerated with age, reaching up to 10% of the progenitor SCs in
adult mice, pointing to a tight connection between p53 LOH and
aging in vivo (unpublished results). This observation raises the
question of whether LOH, as a marker of genomic instability, leads
to aging or whether aging leads to increased LOH. In agreement
with these results, studies in yeast have revealed an increase in
LOH as the mother cell ages [114]. Analysis of the colony forming
units derived from adult mouse bone marrow indicated that in
addition to the well-documented WT p53 LOH, which endows cells
with growth advantage, loss of the mutant allele may also take
place (unpublished results). It seems that in cells that are assumed
to be genomically stable, such as BM progenitors and iPSCs, the loss
of themutant p53 allele is detectedmore frequently than the loss of
theWT allele. Thus it is tempting to speculate that p53 LOH can be a
physiological DNA repair mechanism that helps maintain genomic
integrity. Unfortunately, when this DNA repair mechanism fails and
the WT allele is lost, the ﬁnal outcome will be takeover by the
homozygous mutant p53 cells, leading to accumulation of other
mutations and tumor formation.
5. Facing the future – eliminating CSCs using p53
Conventional anti-cancer therapies kill proliferating cells and
often lead to shrinkage of the tumor. These therapies do not elim-
inate quiescent tumor stem cells that may, with time, arise and
cause relapse of the disease. Thus, while targeting the proliferating
tumor cells is the ﬁrst step in combating cancer, targeting CSCs
may be crucial to ﬁnally eradicating various tumor types. This goal
may be achieved by either differentiation therapy or elimination
therapy. Differentiation therapy is based on the induction of differ-
entiation of CSCs. This process will lead to the loss of their self-re-
newal properties and to susceptibility to DNA damage responses. A
proof of concept was achieved and adopted in clinical practice with
the treatment of acute promyleocytic leukaemia (APL) patients
with all-trans retinoic acid (ATRA). The amazing effect of ATRA as
a differentiation inducer has ﬂipped APL from the most-difﬁcult-
to-treat into the most-easy-to-treat acute leukemia [115]. Simi-
larly, the differentiating agent 13-cis-retinoic acid (RA) is used as
a standard treatment for high-risk neuroblastoma, improving sur-
vival by 35% in children with metastatic neuroblastoma [116]. In
glioblastomas, induction of astrocytic differentiation with bone
morphogenetic proteins (BMPs) reduces the frequency of CD133+
CSCs [117]. Recently, data has been published providing proof-of-
concept that inhibitors targeting mutant isocitrate dehydrogenases
1 and 2 (IDH1 and IDH2) could have potential applications as a dif-
ferentiation therapy for cancer. Treatment with such an inhibitor
(AGI-6780) induced differentiation of TF-1 erythroleukemia and
primary human acute myelogenous leukemia cells in vitro [118].
Another inhibitor of mutant IDH1 was shown to delay growth
and promote differentiation of glioma cells [119]. Other ap-
proaches towards differentiation therapy are based on mediatinggene expression through histone deacetylases [120] and miRNAs
[121]. For example, in glioblastoma, miR-34a targets Notch1 and
Notch2 mRNAs, resulting in CSCs differentiation [122], while
medulloblastoma CSCs undergo neural differentiation by virtue of
miR-34a targeting the Notch ligand Delta-like ligand 1 (DLL1)
[123]. Transfection of either miR-124 or miR-137 into glioblastoma
multiforme CSCs (CD133+) also induces cell cycle arrest and differ-
entiation [124]. The profound role of p53 as a differentiation indu-
cer in various cell types, together with its restricting activity in
processes of dedifferentiation and reprogramming, places p53 as
an attractive candidate for differentiation therapy. Initial data sup-
porting this notion was obtained twenty years ago. Stable and reg-
ulated expression of WT p53 in a pancreatic carcinoma tumor
model was shown to have multiple phenotypic consequences:
the majority of the tumor cells (60–70%) underwent G1 growth ar-
rest and apoptosis while the rest of the cells exhibited irreversible
growth-arrest with morphologic and antigenic properties of a dif-
ferentiated neuroendocrine-like phenotype in vitro [125]. Injection
of lung metastases of human osteogenic sarcoma cells with WT
p53 is associated with in vivo induction of terminal differentiation
and apoptosis, inhibiting progressive growth of metastases [126].
SCs with target mutation in p53 possess the same self-renewal
properties as CSCs and their number increases progressively in
p53 null premalignant mammary glands [127]. Pharmacological
reactivation of p53 correlates with restoration of asymmetric divi-
sion of CSCs and tumor growth reduction [127]. In a model of squa-
mous cell carcinomas (SCCs), one of the most aggressive and
heterogeneous skin cancers, p53 restoration induces skin tumor
cell differentiation and suppression with no apparent effect on
apoptosis, proliferation, or senescence [128].
Another way to combat CSCs is to eliminate them. This could be
achieved by targeting signaling pathway of self-renewal. For exam-
ple, Hedgehog pathway inhibition is emerging as a feasible and
promising therapeutic approach in several cancers and some inhib-
itors that directly target the positive Hedgehog signal transducer
Smoothened (SMO) have entered clinical trials [129]. Attempts to
target CSCs via surface markers were also suggested, although
the expression of these surface markers may vary in different
stages of the disease and may even vary between patients with
the same disease [130]. Another strategy takes advantage of old
chemotherapy drugs and combines them with a CSC targeting
strategy. For example, treating gastric tumor cells, which express
CD90, with trastuzumab (humanized anti-ERBB2 antibody) com-
bined with traditional chemotherapy reduced the CD90+ popula-
tion in tumor mass and suppressed tumor growth [131]. The
same strategy has provided encouraging data in primary ovarian
cancer cell lines and patient-derived xenograft models [132],
non-small cell lung cancer cells [133] and primary colon cancer
cells [134]. Similarly, it was shown that combining a p53 path-
way-restoring agent such as ellipticine with a classical chemother-
apy agent (5-ﬂuoruracil) is associated with depletion of putative
colon CSCs [135]. The mechanism leading to this phenomenon
has yet to be deﬁned, but it is conceivable that restoration of a
functional WT p53 might reduce the expression of the ABC trans-
porters, leading to an increase in the concentration and efﬁcacy
of some anticancer drugs.
6. Concluding remarks
SCs are essential for normal development and are crucial for or-
gan regeneration. Damaged SCs may result in improper develop-
ment, early aging and tumorigenesis. Thus, it is not surprising
that p53 plays a major role in various processes ensuring that
SCs will remain in sufﬁcient quantity and quality. p53 serves as a
barrier between normal SCs and CSCs by preventing processes such
2586 R. Aloni-Grinstein et al. / FEBS Letters 588 (2014) 2580–2589as dedifferentiation and the formation of damaged SCs. Further-
more, p53 LOH is under tight control in genomically stable SCs.
Moreover, in these SCs, the p53 LOH process is targeted towards
the loss of the mutant allele, ensuring quality-controlled functional
SCs (Fig. 1). Further studies aimed at understanding the mecha-
nisms ensuring genomically stabled SCs and the pathways that
lead to CSC formation may contribute to the development of means
to combat cancer.
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